: Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study / E. Ekanem, P. Neuzil, T. Reichlin, J. Kautzner, P. van der Voort, P. Jais, G. Chierchia, A. Bulava, Y. Blaauw, T. Skala, M. Fiala, M. Duytschaever, G. Szeplaki, B. Schmidt, G. Massoullie, K. Neven, O. Thomas, J. Vijgen, E. Gandjbakhch, D. Scherr, A. Johannessen, D. Keane, S. Boveda, P. Maury, I. García-Bolao, A. Anic, P.S. Hansen, F. Raczka, A. Lepillier, Y. Guyomar, D. Gupta, J. Van Opstal, P. Defaye, C. Sticherling, P. Sommer, P. Kucera, J. Osca, F. Tabrizi, A. Roux, M. Gramlich, S. Bianchi, P. Adragão, F. Solimene, C. Tondo, A.D. Russo, J. Schreieck, A. Luik, O. Rana, G. Frommeyer, F. Anselme, I. Kreis, R. Rosso, A. Metzner, L. Geller, S.H. Baldinger, A. Ferrero, S. Willems, A. Goette, G. Mellor, S. Mathew, L. Szumowski, R. Tilz, S. Iacopino, P.K. Jacobsen, A. George, P. Osmancik, S. Spitzer, R. Balasubramaniam, A.S. Parwani, T. Deneke, A. Glowniak, A. Rossillo, H. Pürerfellner, D. Duncker, P. Reil, T. Arentz, D. Steven, J.J. Olalla, J.S.S.G. de Jong, R. Wakili, S. Abbey, G. Timo, A. Asso, T. Wong, B. Pierre, N.C. Ewertsen, L. Bergau, C. Lozano-Granero, M. Rivero, A. Breitenstein, J. Inkovaara, S. Fareh, D.G. Latcu, D. Linz, P. Müller, J. Ramos-Maqueda, T. Beiert, S. Themistoclakis, D.G. Meininghaus, G. Stix, S. Tzeis, J. Baran, H. Almroth, D.R. Munoz, J. de Sousa, M. Efremidis, P. Balsam, J. Petru, T. Küffer, P. Peichl, L. Dekker, D.G. Della Rocca, O. Moravec, M. Funasako, S. Knecht, G. Jauvert, J. Chun, R. Eschalier, A. Füting, A. Zhao, P. Koopman, M. Laredo, M. Manninger, J. Hansen, D. O'Hare, A. Rollin, Z. Jurisic, T. Fink, C. Chaumont, A. Rillig, M. Gunawerdene, C. Martin, B. Kirstein, K. Nentwich, H. Lehrmann, A. Sultan, J. Bohnen, M.K. Turagam, V.Y. Reddy. - In: NATURE MEDICINE. - ISSN 1546-170X. - 30:7(2024), pp. 2020-2029. [10.1038/s41591-024-03114-3]
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
G. Chierchia;S. Bianchi;C. Tondo;
2024
Abstract
: Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.
| File | Dimensione | Formato | |
|---|---|---|---|
|
safety.pdf
accesso aperto
Descrizione: Article
Tipologia:
Publisher's version/PDF
Dimensione
4.25 MB
Formato
Adobe PDF
|
4.25 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
